Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides
This is an open label, single center, non-randomized dose de-escalation phase I study of combination of BV and Mogamulizumab.

The primary objective of the study is to assess the safety and tolerability of the combination. The primary objective is also to explore safe dose of combination for future expansion.
Cutaneous T Cell Lymphoma|Mycosis Fungoides
DRUG: Mogamulizumab|DRUG: Brentuximab vedotin
Rates of Adverse Events, To determine safety, tolerability, and recommended dose of combination of Brentuximab Vedotin and Mogamulizmab in patients with Cutaneous T-Cell Lymphoma and Mycosis Fungoides., through study completion, an average of 1 year|Rates of Serious Adverse Events, To determine safety, tolerability, and recommended dose of combination of Brentuximab Vedotin and Mogamulizmab in patients with Cutaneous T-Cell Lymphoma and Mycosis Fungoides., At the end of cycle 1 (each cycle is 28 days)
Duration of Response, To determine clinical benefit, Overall response rate and Duration of response, through study completion, an average of 1 year|Overall Response rate, To determine clinical benefit, Overall response rate and Duration of response, through study completion, an average of 1 year
This is an open label, single center, non-randomized dose de-escalation phase I study of combination of BV and Mogamulizumab.

The primary objective of the study is to assess the safety and tolerability of the combination. The primary objective is also to explore safe dose of combination for future expansion.